Royal Bank of Canada upgraded shares of Vectura Group (LON:VEC) to a sector performer rating in a research note issued to investors on Thursday. Royal Bank of Canada currently has GBX 119 ($1.60) target price on the stock.

Other equities analysts also recently issued reports about the stock. Numis Securities restated a buy rating and set a GBX 205 ($2.76) target price on shares of Vectura Group in a report on Thursday, October 5th. Panmure Gordon reaffirmed a buy rating on shares of Vectura Group in a research note on Wednesday, August 30th. Shore Capital reaffirmed a buy rating on shares of Vectura Group in a research note on Wednesday, August 16th. Citigroup decreased their price target on shares of Vectura Group from GBX 200 ($2.69) to GBX 180 ($2.42) and set a buy rating on the stock in a research note on Monday, September 18th. Finally, Peel Hunt reaffirmed a hold rating and set a GBX 160 ($2.15) price target on shares of Vectura Group in a research note on Tuesday, October 31st. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of GBX 177.89 ($2.39).

Vectura Group (VEC) opened at GBX 106 ($1.43) on Thursday. Vectura Group has a twelve month low of GBX 86.50 ($1.16) and a twelve month high of GBX 166.97 ($2.25).

COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Upgrades Vectura Group (VEC) to Sector Performer” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.watchlistnews.com/royal-bank-of-canada-upgrades-vectura-group-vec-to-sector-performer/1770602.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.